AstraZeneca $AZN has divested the US rights to its preventative RSV drug, Synagis, to Swedish Orphan Biovitrum AB (Sobi) for $1.5 billion in cash and stock, as the British drugmaker continues to refine its pipeline and focus on its newer flagship products.
